A detailed history of Capital International Investors transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Capital International Investors holds 42,647,759 shares of BMY stock, worth $2.47 Billion. This represents 0.44% of its overall portfolio holdings.

Number of Shares
42,647,759
Previous 55,406,592 23.03%
Holding current value
$2.47 Billion
Previous $2.3 Billion 4.09%
% of portfolio
0.44%
Previous 0.48%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$39.66 - $51.75 $506 Million - $660 Million
-12,758,833 Reduced 23.03%
42,647,759 $2.21 Billion
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $596 Million - $784 Million
-14,797,222 Reduced 21.08%
55,406,592 $2.3 Billion
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $416 Million - $472 Million
8,675,322 Added 14.1%
70,203,814 $3.81 Billion
Q4 2023

Feb 13, 2024

SELL
$48.48 - $57.85 $383 Million - $457 Million
-7,891,438 Reduced 11.37%
61,528,492 $3.16 Billion
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $7.17 Million - $8.02 Million
123,924 Added 0.18%
69,419,930 $4.03 Billion
Q2 2023

Aug 11, 2023

BUY
$63.71 - $70.74 $502 Million - $557 Million
7,878,833 Added 12.83%
69,296,006 $4.43 Billion
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $572 Million - $648 Million
8,700,136 Added 16.5%
61,417,173 $4.26 Billion
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $22 Million - $26 Million
320,605 Added 0.61%
52,717,037 $3.79 Billion
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $1.86 Million - $1.1 Billion
14,298,520 Added 37.53%
52,396,432 $3.73 Billion
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $1.1 Billion - $1.22 Billion
15,196,981 Added 66.36%
38,097,912 $2.93 Billion
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $1.41 Billion - $1.69 Billion
22,900,931 New
22,900,931 $1.67 Billion

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.